APSR2026-975

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP11-026
P68
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1204446-46904-APSR2026-975_439577.pdf
Format: PDF Only
09. Asthma
15

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

David Price * Observational and Pragmatic Research Institute Director's Office Singapore Singapore Optimum Patient Care Global Director's Office Cambridge United Kingdom University of Aberdeen Centre of Academic Primary Care, Division of Applied Health Sciences Aberdeen United Kingdom
Chin Kook Rhee - Konkuk University School of Medicine Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Konkuk University Medical Center Seoul Republic of Korea
Mariko Siyue Koh - Singapore General Hospital Department of Respiratory and Critical Care Medicine Singapore Singapore Duke-National University Singapore Medical School N.A. Singapore Singapore
Trung Tran - AstraZeneca BioPharmaceuticals Medical Gaithersburg United States
Tancy Zhang - AstraZeneca BioPharmaceuticals Medical Gaithersburg United States
Dominic Friston - Observational and Pragmatic Research Institute N.A. Singapore Singapore Optimum Patient Care N.A. Cambridge United Kingdom
Angelica Tatam - Observational and Pragmatic Research Institute N.A. Singapore Singapore Optimum Patient Care Global N.A. Cambridge United Kingdom
Yi-Han Hsiao - Taipei Veterans General Hospital Division of General Chest Medicine, Department of Chest Medicine Taipei Taiwan National Yang Ming Chiao Tung University School of Medicine, College of Medicine Taipei Taiwan
Mei Fong Liew - National University Health System FAST and Chronic Programmes, Alexandra Hospital Singapore Singapore National University Health System Division of Respiratory and Critical Care Medicine, Department of Medicine, National University Hospita Singapore Singapore
Pee Hwee Pang - Tan Tock Seng Hospital Department of Respiratory & Critical Care Medicine Singapore Singapore
Tunn Ren Tay - Changi General Hospital Department of Respiratory and Critical Care Medicine Singapore Singapore
Christopher Watson - AstraZeneca International N.A. Dubai United Arab Emirates
Alexander Chernikov - AstraZeneca Russia and Eurasia Medical department, Biopharma Moscow Russian Federation
Diahn-Warng Perng - National Yang Ming Chiao Tung University School of Medicine Taipei Taiwan Taipei Veterans General Hospital Department of Chest Medicine Taipei Taiwan
Takashi Iwanaga - Osaka Saiseikai Tondabayashi Hospital N.A. Tondabayashi Japan The Kinki Hokuriku Airway Disease Conference (KiHAC) N.A. Osaka Japan
Presenting Author Details
David
Price
dprice@opri.sg
+6582822594
61-70
Singapore
Original Research
Registry-driven improvement in data collection quality to enhance clinical and research impact: insights from the International Severe Asthma Registry (ISAR) in East and Southeast Asia
Maximum 25 words
Abstract Content
Centres of excellence can be accredited via and benefit from bidirectional relationships with wider clinical registries in performance evaluation, quality improvement and research. However, they rely on high data accuracy and completion. This analysis describes changes in data completion across four countries in East and Southeast Asia during ISAR enrolment, as proof of concept for registry-driven development of data infrastructure to support centres of excellence.
ISAR’s key research variables were deemed essential for research and clinical practice by a previous international Delphi study. We assessed annual data completion rates for these variables (16 at first visit, 10 at annual review) in Japan, South Korea, Taiwan and Singapore between their ISAR enrolment year (2019, 2019, 2020 and 2022 respectively) and 2026. We calculated mean completion rates of all variables, the proportion of patients with all key variables recorded, and individual variable completion rates.
2,824 encounters from 1,197 patients were evaluated. Mean completion rates of all variables improved for first visits (92.9 to 94.8%) and annual reviews (90.4 to 95.1%) across all four countries between enrolment year and 2026. The proportion of encounters with all variables recorded rose from 48.0% to 59.5% (completion OR 1.59, 95% CI 1.31–1.94; p<0.0001). Marked improvement was seen in long-term oral corticosteroid (e.g. +14% in medication status and dose in South Korea) and biologic completeness (e.g. +23% in therapy switch reason in Taiwan). Progress was also observed in historically challenging variables such as IgE count, which improved in all individual countries (+3-23%; regional completion 55.7 to73.0%).
Registry engagement, guided by defined data standards, was associated with improved data completeness across the Asian regions. This supports the role of registry governance in driving standardised, high-quality data collection and that a pre-defined variable list and engagement model could be used as the basis for Centre of Excellence designation.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
data completeness, clinical registry, centre of excellence
maximum 3 keywords and no abbreviations, separated by commas
David B. Price has advisory board membership with AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, OM Pharma, Novartis, Viatris, Teva Pharmaceuticals; consultancy agreements with AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Viatris, Teva Pharmaceuticals; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Chiesi, Viatris, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, and UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Inside Practice, GlaxoSmithKline, Med Maps, Medscape, Viatris, Novartis, Regeneron Pharmaceuticals and Sanofi Genzyme, Teva Pharmaceuticals; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, OM Pharma, Novartis, Medscape; honorarium from Apogee, Chiesi, GlaxoSmithKline, OM Pharma; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 92.61% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); is peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation Programme, and Health Technology Assessment; and he was an expert witness for GlaxoSmithKline. Chin Kook Rhee received consulting/lecture fees from Merck Sharp & Dohme, AstraZeneca, GSK, Novartis, Takeda, Mundipharma, Boehringer Ingelheim, Teva, Sanofi, Organon, Roche, and Bayer. Mariko Siyue Koh reports grant support from AstraZeneca, and honoraria for lectures and advisory board meetings paid to her hospital (Singapore General Hospital) from GSK, AstraZeneca, Novartis, Sanofi, and Boehringer Ingelheim, outside the submitted work. Trung N. Tran is an employee of AstraZeneca and may own stock or stock options in AstraZeneca. AstraZeneca is a co-funder of the International Severe Asthma Registry. Tancy C. Zhang is an employee of AstraZeneca and may own stocks or stock options in AstraZeneca. AstraZeneca is a co-funder of the International Severe Asthma Registry. Dominic A. Friston is an employee of Optimum Patient Care (OPC). OPC is a co-funder of the International Severe Asthma Registry. Angelica Tatam is an employee of Optimum Patient Care Global, a co-funder of the International Severe Asthma Registry. Yi-Han Hsiao received honoraria for lectures from Boehringer Ingelheim, Sanofi, GSK, AstraZeneca, Novartis, and Orient EuroPharma (OEP). He also received support for attending meetings and/or travel from Sanofi, GSK, and AstraZeneca. Mei Fong Liew declares honoraria for lectures and advisory board meetings paid to her hospital (Alexandra Hospital) from GSK, AstraZeneca, and Sanofi, outside the submitted work. Pee Hwee Pang has received honoraria for talks and advisory board meetings from GSK, AstraZeneca, and Sanofi. Tunn Ren Tay has received speaker fees and advisory board payments from AstraZeneca, GSK and Sanofi paid to her institution and outside of the submitted work. Christopher P. Watson is an employee of AstraZeneca and may own stock or stock options in AstraZeneca. AstraZeneca is a co-funder of the International Severe Asthma Registry. Alexander Chernikov is an employee of AstraZeneca and may own stock or stock options in AstraZeneca. AstraZeneca is a co-funder of the International Severe Asthma Registry. Diahn-Warng Perng received a sponsorship to attend or speak at international meetings, honoraria for lecturing or attending advisory boards, and research grants from the following companies: AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Daiichi Sankyo, Shionogi, and Orient Pharma. Takashi Iwanaga received speaker bureau fees from Kyorin, GSK, Boehringer Ingelheim, Novo Nordisk, Tanabe Pharma, and AstraZeneca.
317